1117PDPembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy

ConclusionsThis is the first study to report acute toxicities of combining pembrolizumab with radiation in LA-HNSCC. Pembrolizumab does not potentiate typical XRT associated toxicities and no unexpected immune related adverse events were observed. Further, lower rates of feeding tube placement and grade 3/4 dermatitis, xerostomia, and mucositis were noted when compared to RTOG1016 (concurrent XRT with cisplatin or cetuximab in LA-HNSCC).Clinical trial identificationNCT02609503.Legal entity responsible for the studyThe authors.FundingMerck Sharp& Dohme Corp.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research